iuvo BioScience Toxicologist Dr. Cheryl Marker was coauthor of a paper that was published in the February 2023 issue of Cell Reports entitled “A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl”. Dr. Marker works in the Lumino Advisors consulting group, as part of iuvo’s consulting team. Opioid […]
At iuvo, we work hard to stay on the cutting edge of new developments in testing and regulatory changes affecting the medical device and pharmaceutical industries. We will share these updates regularly here in our blog - Exhaustive Extractions.
Due to the extreme generosity of our iuvo family, we were able to provide gifts for a mom and her five kids, along with dry food goods, and grocery store and Amazon gift cards. Wow!!! This kindness surely has an impact.
iuvo BioScience teams up with CAS IP Services to achieve its mission of helping clients move new products from research to release faster and at a lower cost. iuvo relies on data from CAS scientific and intellectual property searches to help their clients drive decisions in preclinical research, toxicology testing, and regulatory submissions. The data […]
The PQRI Parenteral and Ophthalmic Drug Product Leachables and Extractables (PODP L&E) Working Group has posted a brief update on their work to develop a risked–based approach for evaluation and safety qualification of leachables in PODPs, and Dr. Mary Richardson, iuvo’s Chief Scientific Officer, is a member of the PQRI Working Group. The update is […]
When developing a new pharmaceutical product, it is important to assemble the right team with the right expertise to enable an effective development program with the highest probability of success. For startup companies who are focused on one or two assets, it frequently is not possible to hire all the individual specialties required to develop […]
Drs. Mary Richardson and Kathleen Krenzer co-authored a guest blog for Hall Analytical Laboratories on biocompatibility in the characterization of medical devices. The blog post can be found here.
December 21, 2020 – For the fourth year in a row, the iuvo BioScience Community Outreach Team adopted a family in need to help provide for the Christmas holiday. The family provided a wish list, and iuvo was able to give gifts to them, including several boxes of food and gift cards. Delivery was made […]
September 18, 2020 – iuvo BioScience is one of two local companies partnering with Rochester Regional Health to assist with the increasing demand for coronavirus testing. There has been a shortage of Transport Media, so iuvo teamed up with the healthcare provider to produce this essential part of the test kit. “The local ecosystem that […]
September 8, 2020 – The FDA issued a guidance document on September 4, 2020, on Use of International Standard ISO 10993-1, “Biological Evaluation of Medical Devices – Part 1: Evaluation and testing within a risk management process”. This document is available on the FDA’s website here. This guidance document, which supersedes the 2016 version of […]
March 8, 2020 – iuvo’s Dr. Mary Richardson and Dr. Kathleen Krenzer, members of iuvo’s Lumino Advisors Consulting Group, guest-taught a class on biocompatibility to a group of biomedical engineers on Friday, March 6. The class was a graduate level class taught by Dr. Greg Gdowski at the University of Rochester’s Department of Biomedical Engineering, […]